Central Nervous System Drugs MGR 2017
July 2017
125
About the Report
About the Report
Central nervous system drugs market include medications that are used in the treatment of diseases affecting the brain or spinal cord. The major diseases in the market include bipolar disorders, anxiety, depression, Parkinson's disease, Alzheimer's disease, and epilepsy. Top selling neurological drugs in 2016 include Copaxone, Lyrica, and Tecfidera.
The global central nervous system drugs market was estimated to be around $68 billion as of 2016. The central nervous system drugs market made up around 6% of the overall pharmaceuticals market in 2016. The central nervous system drugs market was the eighth largest market in the global pharmaceutical market in 2016.
Regenerative Therapies For Central Nervous System Diseases
Regenerative therapies for the treatment of central nervous system diseases is one of the emerging trend in the global central nervous system drugs market. These therapies will help in the healing process by replacing or regenerating human cells, tissues, and organs. The major regenerative therapies include transplantation by embryonic stem cells, usage of matrix such as fibrin, collagen, and hyaluronic acid.
The Central Nervous System Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs sector.
Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the central nervous system drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The central nervous system drugs market section of the report gives context. It compares the central nervous system drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Central Nervous System Drugs Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Analgesics, Anti-Parkinson Drugs, Anaesthetics, Anti-Epileptics, Other CNS Drugs
Companies Mentioned: Pfizer Inc., Biogen Idec, Novartis AG, Otsuka, and Teva Pharmaceuticals
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Central Nervous System Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Products
Products
Analgesics, Anti-Parkinson Drugs, Anaesthetics, Anti-Epileptics, Other CNS Drugs
Companies
Pfizer Inc., Biogen Idec, Novartis AG, Otsuka, and Teva Pharmaceuticals
Table of Contents
Table of Contents
1. Central Nervous System Drugs Market Characteristics;
2. Central Nervous System Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Central Nervous System Drugs Market Customer Information;
5. Central Nervous System Drugs Market Segmentation;
5.1. Global Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 5.2. Global Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Central Nervous System Drugs Market Trends And Strategies;
6. Central Nervous System Drugs Market Regional And Country Analysis;
6.1. Global Central Nervous System Drugs Market, 2016, By Region; 6.2. Global Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Central Nervous System Drugs Market, 2016, By Country; 6.4. Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6 Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7 Global Pharmaceutical Market Segments, 2016, By Country; 6.8 Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Central Nervous System Drugs Market Comparison With Macro Economic Factors;
7.1. Central Nervous System Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Central Nervous System Drugs Expenditure, Global;
8. Central Nervous System Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Central Nervous System Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Central Nervous System Drugs Expenditure, By Country;
9. Central Nervous System Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Central Nervous System Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Central Nervous System Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Central Nervous System Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Central Nervous System Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.10. Global Number Of Psychiatrists, 2016, By Country; 9.11. Global Central Nervous System Drugs Market Revenue Versus Number Of Psychiatrists, 2016, By Country; 9.12. Global Number Of General Practitioners 2016, By Country; 9.13. Global Central Nervous System Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Central Nervous System Drugs Market;
10.1.1. Asia-Pacific Central Nervous System Drugs Market Overview; 10.1.2. Asia-Pacific Central Nervous System Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Central Nervous System Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.2. Asia-Pacific Central Nervous System Drugs Market: Country Analysis; 10.3. China Central Nervous System Drugs Market; 10.3.1. China Central Nervous System Drugs Market Overview; 10.3.2. China Central Nervous System Drugs Historic Market, 2012-2016; 10.3.3. China Central Nervous System Drugs Forecast Market, 2016-2020; 10.3.4. China Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.3.5. China Central Nervous System Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 10.4. India Central Nervous System Drugs Market; 10.4.1. India Central Nervous System Drugs Market Overview; 10.4.2. India Central Nervous System Drugs Historic Market, 2012-2016; 10.4.3. India Central Nervous System Drugs Forecast Market, 2016-2020; 10.4.4. India Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.4.5. India Central Nervous System Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 10.5. Japan Central Nervous System Drugs Market; 10.5.1. Japan Central Nervous System Drugs Market Overview; 10.5.2. Japan Central Nervous System Drugs Historic Market, 2012-2016; 10.5.3. Japan Central Nervous System Drugs Forecast Market, 2016-2020; 10.5.4. Japan Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.5.5. Japan Central Nervous System Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 10.6. Australia Central Nervous System Drugs Market; 10.6.1. Australia Central Nervous System Drugs Historic Market, 2012-2016; 10.6.2. Australia Central Nervous System Drugs Forecast Market, 2016-2020; 10.6.3. Australia Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.6.4. Australia Central Nervous System Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020;
11. Western Europe Central Nervous System Drugs Market;
11.1.1. Western Europe Central Nervous System Drugs Market Overview; 11.1.2. Western Europe Central Nervous System Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Central Nervous System Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.2. Western Europe Central Nervous System Drugs Market: Country Analysis; 11.3. UK Central Nervous System Drugs Market; 11.3.1. UK Central Nervous System Drugs Market Overview; 11.3.2. UK Central Nervous System Drugs Historic Market, 2012-2016; 11.3.3. UK Central Nervous System Drugs Forecast Market, 2016-2020; 11.3.4. UK Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.3.5. UK Central Nervous System Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 11.4. Germany Central Nervous System Drugs Market; 11.4.1. Germany Central Nervous System Drugs Historic Market, 2012-2016; 11.4.2. Germany Central Nervous System Drugs Forecast Market, 2016-2020; 11.4.3. Germany Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.4.4 Germany Central Nervous System Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 11.5 France Central Nervous System Drugs Market; 11.5.1 France Central Nervous System Drugs Historic Market, 2012-2016; 11.5.2 France Central Nervous System Drugs Forecast Market, 2016-2020; 11.5.3 France Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.5.4 France Central Nervous System Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 11.6. Italy Central Nervous System Drugs Market; 11.6.1. Italy Central Nervous System Drugs Historic Market, 2012-2016; 11.6.2. Italy Central Nervous System Drugs Forecast Market, 2016-2020; 11.6.3. Italy Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.6.4. Italy Central Nervous System Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 11.7. Spain Central Nervous System Drugs Market; 11.7.1. Spain Central Nervous System Drugs Historic Market, 2012-2016; 11.7.2. Spain Central Nervous System Drugs Forecast Market, 2016-2020; 11.7.3. Spain Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.7.4. Spain Central Nervous System Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020; 12. Eastern Europe Central Nervous System Drugs Market;
12. Eastern Europe Central Nervous System Drugs Market;
12.1.1. Eastern Europe Central Nervous System Drugs Market Overview; 12.1.2. Eastern Europe Central Nervous System Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Central Nervous System Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 12.2. Eastern Europe Central Nervous System Drugs Market: Country Analysis; 12.3. Russia Central Nervous System Drugs Market; 12.3.1. Russia Central Nervous System Drugs Historic Market, 2012-2016; 12.3.2. Russia Central Nervous System Drugs Forecast Market, 2016-2020; 12.3.3. Russia Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 12.3.4. Russia Central Nervous System Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020;
13. North America Central Nervous System Drugs Market;
13.1.1. North America Central Nervous System Drugs Market Overview; 13.1.2. North America Central Nervous System Drugs Historic Market, 2012-2016; 13.1.3. North America Central Nervous System Drugs Forecast Market, 2016-2020; 13.1.4. North America Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 13.2. North America Central Nervous System Drugs Market: Country Analysis; 13.3. USA Central Nervous System Drugs Market; 13.3.1. USA Central Nervous System Drugs Historic Market, 2012-2016; 13.3.2. USA Central Nervous System Drugs Forecast Market, 2016-2020; 13.3.3 USA Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 13.3.4. USA Central Nervous System Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020;
14. South America Central Nervous System Drugs Market;
14.1.1. South America Central Nervous System Drugs Market Overview; 14.1.2. South America Central Nervous System Drugs Historic Market, 2012-2016; 14.1.3. South America Central Nervous System Drugs Forecast Market, 2016-2020; 14.1.4. South America Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 14.2. South America Central Nervous System Drugs Market: Country Analysis; 14.3. Brazil Central Nervous System Drugs Market; 14.3.1. Brazil Central Nervous System Drugs Historic Market, 2012-2016; 14.3.2. Brazil Central Nervous System Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 14.3.4. Brazil Central Nervous System Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020;
15. Middle East Central Nervous System Drugs Market;
15.1.1. Middle East Central Nervous System Drugs Market Overview; 15.1.2. Middle East Central Nervous System Drugs Historic Market, 2012-2016; 15.1.3. Middle East Central Nervous System Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs;
16. Africa Central Nervous System Drugs Market;
16.1.1. Africa Central Nervous System Drugs Market Overview; 16.1.2. Africa Central Nervous System Drugs Historic Market, 2012-2016; 16.1.3. Africa Central Nervous System Drugs Forecast Market, 2016-2020; 16.1.4. Africa Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics;
17. Central Nervous System Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Pfizer Inc.; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Biogen Idec; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Otsuka; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Teva Pharmaceuticals; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Central Nervous System Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
List of Figure
Table 1: Global Central Nervous System Drugs Historic Market Growth
Table 2: Global Central Nervous System Drugs Forecast Market Growth
Table 3: Central Nervous System Drugs Market Segmentation
Table 4: Global Central Nervous System Drugs Market, 2016, By Segment
Table 5: Global Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Segment
Table 6: Global Central Nervous System Drugs Market, 2016, By Region
Table 7: Global Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 8: Central Nervous System Drugs Market, 2016, By Country
Table 9: Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 10: Global Pharmaceutical Market Segments, 2016, By Region
Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Table 12: Global Pharmaceutical Market Segments, 2016, By Country
Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Table 14: Central Nervous System Drugs Market Size, Percentage Of GDP, Global
Table 15: Per Capita Average Central Nervous System Drugs Expenditure, Global
Table 16: Central Nervous System Drugs Market Comparison With Macro Economic Factors Across Countries
Table 17: Central Nervous System Drugs Market Size, Percentage Of GDP, By Country
Table 18: Per Capita Average Central Nervous System Drugs Expenditure, By Country
Table 19: Global Number Of Pharmacists, 2016, By Country
Table 20: Global Central Nervous System Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 21: Global Number Of Pharma Enterprises, 2016, By Country
Table 22: Global Central Nervous System Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 23: Global Average Spending On R&D/Product Development, 2016, By Country
Table 24: Global Central Nervous System Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 26: Global Central Nervous System Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 27: Prevalent Cases Of Parkinsons Disease, 2014, By Country
Table 28: Global Number Of Psychiatrists, 2016, By Country
Table 29: Global Central Nervous System Drugs Market Revenue Versus Number Of Psychiatrists, 2016, By Country
Table 30: Global Number Of General Practitioners 2016, By Country
Table 31: Global Central Nervous System Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
Table 32: Asia-Pacific Central Nervous System Drugs Historic Market, 2012-2016
Table 33: Asia-Pacific Central Nervous System Drugs Forecast Market, 2016-2020
Table 34: Asia-Pacific Central Nervous System Drugs Market, 2016, By Segment
Table 35: China Central Nervous System Drugs Historic Market, 2012-2016
Table 36: China Central Nervous System Drugs Forecast Market, 2016-2020
Table 37: China Central Nervous System Drugs Market, 2016, By Segment
Table 38: China Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 39: China Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 40: India Central Nervous System Drugs Historic Market, 2012-2016
Table 41: India Central Nervous System Drugs Forecast Market, 2016-2020
Table 42: India Central Nervous System Drugs Market, 2016, By Segment
Table 43: India Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 44: India Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 45: Japan Central Nervous System Drugs Historic Market, 2012-2016
Table 46: Japan Central Nervous System Drugs Forecast Market, 2016-2020
Table 47: Japan Central Nervous System Drugs Market, 2016, By Segment
Table 48: Japan Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 49: Japan Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 50: Australia Central Nervous System Drugs Historic Market, 2012-2016
Table 51: Australia Central Nervous System Drugs Forecast Market, 2016-2020
Table 52: Australia Central Nervous System Drugs Market, 2016, By Segment
Table 53: Australia Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 54: Australia Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 55: Western Europe Central Nervous System Drugs Historic Market, 2012-2016
Table 56: Western Europe Central Nervous System Drugs Forecast Market, 2016-2020
Table 57: Western Europe Central Nervous System Drugs Market, 2016, By Segment
Table 58: UK Central Nervous System Drugs Historic Market, 2012-2016
Table 59: UK Central Nervous System Drugs Forecast Market, 2016-2020
Table 60: UK Central Nervous System Drugs Market, 2016, By Segment
Table 61: UK Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 62: UK Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 63: Germany Central Nervous System Drugs Historic Market, 2012-2016
Table 64: Germany Central Nervous System Drugs Forecast Market, 2016-2020
Table 65: Germany Central Nervous System Drugs Market, 2016, By Segment
Table 66: Germany Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 67: Germany Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 68: France Central Nervous System Drugs Historic Market, 2012-2016
Table 69: France Central Nervous System Drugs Forecast Market, 2016-2020
Table 70: France Central Nervous System Drugs Market, 2016, By Segment
Table 71: France Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 72: France Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 73: Italy Central Nervous System Drugs Historic Market, 2012-2016
Table 74: Italy Central Nervous System Drugs Forecast Market, 2016-2020
Table 75: Italy Central Nervous System Drugs Market, 2016, By Segment
Table 76: Italy Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 77: Italy Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 78: Spain Central Nervous System Drugs Historic Market, 2012-2016
Table 79: Spain Central Nervous System Drugs Forecast Market, 2016-2020
Table 80: Spain Central Nervous System Drugs Market, 2016, By Segment
Table 81: Spain Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 82: Spain Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 83: Eastern Europe Central Nervous System Drugs Historic Market, 2012-2016
Table 84: Eastern Europe Central Nervous System Drugs Forecast Market, 2016-2020
Table 85: Eastern Europe Central Nervous System Drugs Market, 2016, By Segment
Table 86: Russia Central Nervous System Drugs Historic Market, 2012-2016
Table 87: Russia Central Nervous System Drugs Forecast Market, 2016-2020
Table 88: Russia Central Nervous System Drugs Market, 2016, By Segment
Table 89: Russia Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 90: Russia Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 91: North America Central Nervous System Drugs Historic Market, 2012-2016
Table 92: North America Central Nervous System Drugs Forecast Market, 2016-2020
Table 93: North America Central Nervous System Drugs Market, 2016, By Segment
Table 94: USA Central Nervous System Drugs Historic Market, 2012-2016
Table 95: USA Central Nervous System Drugs Forecast Market, 2016-2020
Table 96: USA Central Nervous System Drugs Market, 2016, By Segment
Table 97: USA Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 98: USA Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 99: South America Central Nervous System Drugs Historic Market, 2012-2016
Table 100: South America Central Nervous System Drugs Forecast Market, 2016-2020
Table 101: South America Central Nervous System Drugs Market, 2016, By Segment
Table 102: Brazil Central Nervous System Drugs Historic Market, 2012-2016
Table 103: Brazil Central Nervous System Drugs Forecast Market, 2016-2020
Table 104: Brazil Central Nervous System Drugs Market, 2016, By Segment
Table 105: Brazil Central Nervous System Drugs Percentage Of GDP, 2012-2020
Table 106: Brazil Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Table 107: Middle East Central Nervous System Drugs Historic Market, 2012-2016
Table 108: Middle East Central Nervous System Drugs Forecast Market, 2016-2020
Table 109: Middle East Central Nervous System Drugs Market, 2016, By Segment
Table 110: Africa Central Nervous System Drugs Historic Market, 2012-2016
Table 111: Africa Central Nervous System Drugs Forecast Market, 2016-2020
Table 112: Africa Central Nervous System Drugs Market, 2016, By Segment
Table 113: Pfizer Inc. Financial Performance
Table 114: Biogen Idec Financial Performance
Table 115: Novartis Ag Financial Performance
Table 116: Otsuka Financial Performance
Table 117: Teva Pharmaceuticals Financial Performance
Table 118: Pharmaceutical Drugs Market Historic Growth
Table 119: Pharmaceutical Drugs Market Forecast Growth
Table 120: Global Pharmaceutical Drugs Market, 2016, By Region
Table 121: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Table 122: Pharmaceutical Drugs Market, 2016, By Country
Table 123: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Table 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Table 125: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Table 126: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Table 127: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Table 128: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Table 129: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Table 130: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Table 131: Pharmaceuticals Industry Financial Margins
List of Table
Figure 1: Global Central Nervous System Drugs Historic Market Growth
Figure 2: Global Central Nervous System Drugs Forecast Market Growth
Figure 3: Central Nervous System Drugs Market Segmentation
Figure 4: Global Central Nervous System Drugs Market, 2016, By Segment
Figure 5: Global Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Segment
Figure 6: Global Central Nervous System Drugs Market, 2016, By Region
Figure 7: Global Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 8: Central Nervous System Drugs Market, 2016, By Country
Figure 9: Central Nervous System Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 10: Global Pharmaceutical Market Segments, 2016, By Region
Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region
Figure 12: Global Pharmaceutical Market Segments, 2016, By Country
Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country
Figure 14: Central Nervous System Drugs Market Size, Percentage Of GDP, Global
Figure 15: Per Capita Average Central Nervous System Drugs Expenditure, Global
Figure 16: Central Nervous System Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 17: Central Nervous System Drugs Market Size, Percentage Of GDP, By Country
Figure 18: Per Capita Average Central Nervous System Drugs Expenditure, By Country
Figure 19: Global Number Of Pharmacists, 2016, By Country
Figure 20: Global Central Nervous System Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 21: Global Number Of Pharma Enterprises, 2016, By Country
Figure 22: Global Central Nervous System Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 24: Global Central Nervous System Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 26: Global Central Nervous System Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 27: Prevalent Cases Of Parkinsons Disease, 2014, By Country
Figure 28: Global Number Of Psychiatrists, 2016, By Country
Figure 29: Global Central Nervous System Drugs Market Revenue Versus Number Of Psychiatrists, 2016, By Country
Figure 30: Global Number Of General Practitioners 2016, By Country
Figure 31: Global Central Nervous System Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
Figure 32: Asia-Pacific Central Nervous System Drugs Historic Market, 2012-2016
Figure 33: Asia-Pacific Central Nervous System Drugs Forecast Market, 2016-2020
Figure 34: Asia-Pacific Central Nervous System Drugs Market, 2016, By Segment
Figure 35: China Central Nervous System Drugs Historic Market, 2012-2016
Figure 36: China Central Nervous System Drugs Forecast Market, 2016-2020
Figure 37: China Central Nervous System Drugs Market, 2016, By Segment
Figure 38: China Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 39: China Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 40: India Central Nervous System Drugs Historic Market, 2012-2016
Figure 41: India Central Nervous System Drugs Forecast Market, 2016-2020
Figure 42: India Central Nervous System Drugs Market, 2016, By Segment
Figure 43: India Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 44: India Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 45: Japan Central Nervous System Drugs Historic Market, 2012-2016
Figure 46: Japan Central Nervous System Drugs Forecast Market, 2016-2020
Figure 47: Japan Central Nervous System Drugs Market, 2016, By Segment
Figure 48: Japan Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 49: Japan Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 50: Australia Central Nervous System Drugs Historic Market, 2012-2016
Figure 51: Australia Central Nervous System Drugs Forecast Market, 2016-2020
Figure 52: Australia Central Nervous System Drugs Market, 2016, By Segment
Figure 53: Australia Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 54: Australia Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 55: Western Europe Central Nervous System Drugs Historic Market, 2012-2016
Figure 56: Western Europe Central Nervous System Drugs Forecast Market, 2016-2020
Figure 57: Western Europe Central Nervous System Drugs Market, 2016, By Segment
Figure 58: UK Central Nervous System Drugs Historic Market, 2012-2016
Figure 59: UK Central Nervous System Drugs Forecast Market, 2016-2020
Figure 60: UK Central Nervous System Drugs Market, 2016, By Segment
Figure 61: UK Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 62: UK Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 63: Germany Central Nervous System Drugs Historic Market, 2012-2016
Figure 64: Germany Central Nervous System Drugs Forecast Market, 2016-2020
Figure 65: Germany Central Nervous System Drugs Market, 2016, By Segment
Figure 66: Germany Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 67: Germany Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 68: France Central Nervous System Drugs Historic Market, 2012-2016
Figure 69: France Central Nervous System Drugs Forecast Market, 2016-2020
Figure 70: France Central Nervous System Drugs Market, 2016, By Segment
Figure 71: France Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 72: France Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 73: Italy Central Nervous System Drugs Historic Market, 2012-2016
Figure 74: Italy Central Nervous System Drugs Forecast Market, 2016-2020
Figure 75: Italy Central Nervous System Drugs Market, 2016, By Segment
Figure 76: Italy Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 77: Italy Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 78: Spain Central Nervous System Drugs Historic Market, 2012-2016
Figure 79: Spain Central Nervous System Drugs Forecast Market, 2016-2020
Figure 80: Spain Central Nervous System Drugs Market, 2016, By Segment
Figure 81: Spain Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 82: Spain Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 83: Eastern Europe Central Nervous System Drugs Historic Market, 2012-2016
Figure 84: Eastern Europe Central Nervous System Drugs Forecast Market, 2016-2020
Figure 85: Eastern Europe Central Nervous System Drugs Market, 2016, By Segment
Figure 86: Russia Central Nervous System Drugs Historic Market, 2012-2016
Figure 87: Russia Central Nervous System Drugs Forecast Market, 2016-2020
Figure 88: Russia Central Nervous System Drugs Market, 2016, By Segment
Figure 89: Russia Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 90: Russia Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 91: North America Central Nervous System Drugs Historic Market, 2012-2016
Figure 92: North America Central Nervous System Drugs Forecast Market, 2016-2020
Figure 93: North America Central Nervous System Drugs Market, 2016, By Segment
Figure 94: USA Central Nervous System Drugs Historic Market, 2012-2016
Figure 95: USA Central Nervous System Drugs Forecast Market, 2016-2020
Figure 96: USA Central Nervous System Drugs Market, 2016, By Segment
Figure 97: USA Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 98: USA Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 99: South America Central Nervous System Drugs Historic Market, 2012-2016
Figure 100: South America Central Nervous System Drugs Forecast Market, 2016-2020
Figure 101: South America Central Nervous System Drugs Market, 2016, By Segment
Figure 102: Brazil Central Nervous System Drugs Historic Market, 2012-2016
Figure 103: Brazil Central Nervous System Drugs Forecast Market, 2016-2020
Figure 104: Brazil Central Nervous System Drugs Market, 2016, By Segment
Figure 105: Brazil Central Nervous System Drugs Percentage Of GDP, 2012-2020
Figure 106: Brazil Per Capita Average Central Nervous System Drugs Expenditure, 2012-2020
Figure 107: Middle East Central Nervous System Drugs Historic Market, 2012-2016
Figure 108: Middle East Central Nervous System Drugs Forecast Market, 2016-2020
Figure 109: Middle East Central Nervous System Drugs Market, 2016, By Segment
Figure 110: Africa Central Nervous System Drugs Historic Market, 2012-2016
Figure 111: Africa Central Nervous System Drugs Forecast Market, 2016-2020
Figure 112: Africa Central Nervous System Drugs Market, 2016, By Segment
Figure 113: Pfizer Inc. Financial Performance
Figure 114: Biogen Idec Financial Performance
Figure 115: Novartis Ag Financial Performance
Figure 116: Otsuka Financial Performance
Figure 117: Teva Pharmaceuticals Financial Performance
Figure 118: Pharmaceutical Drugs Market Historic Growth
Figure 119: Pharmaceutical Drugs Market Forecast Growth
Figure 120: Global Pharmaceutical Drugs Market, 2016, By Region
Figure 121: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region
Figure 122: Pharmaceutical Drugs Market, 2016, By Country
Figure 123: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country
Figure 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Figure 125: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Figure 126: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Figure 127: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Figure 128: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 129: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Figure 130: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Figure 131: Pharmaceuticals Industry Financial Margins
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.